5-HTP for Health & Longevity - Quick Reference Sheet

5-HTP for Health & Longevity

Created on 09/13/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

An inexpensive substance one step before serotonin, sold without prescription. Best supported for low mood and for appetite and body weight; weaker signals for poor sleep, thinking in older adults and widespread muscle pain. Many trials are small, old and never independently repeated. Nausea and diarrhoea are common; the main hazard is combining it with anything that raises serotonin. (Full Review)

Protocol

Standard mood protocol
100 mg, two to three times daily
Matches the 150-300 mg daily range of the European antidepressant trials
Sleep protocol
100 mg, 30-60 minutes before bed
Regimen used in the Singapore older-adult trials
Appetite and weight protocol
750-900 mg daily, divided before meals
Correspondingly higher gastrointestinal burden; rarely sustained
Time to effect
Mood effects
2-4 weeks
Consistent with antidepressant timelines generally
Appetite suppression
First few days to 2 weeks
Early satiety and reduced carbohydrate intake
Sleep changes
First few days to 2 weeks
Sleep-quality gain confined to poor sleepers

Benefits

Contraindications
  • Monoamine oxidase inhibitors, or within 14 days of stopping one
  • Pregnancy or breastfeeding
  • Carcinoid syndrome or other serotonin-secreting neuroendocrine tumour
  • Bipolar I or II disorder, or a psychotic disorder, unless supervised by a psychiatrist
  • Moderate or severe valvular heart disease (moderate-or-worse regurgitation)
  • Prior eosinophilia-myalgia syndrome, or unexplained eosinophilia above 1,500 cells/µL
  • Child-Pugh Class B or C liver impairment
  • Under 18, outside a specialist neurological indication
Key Interactions
  • Serotonin reuptake inhibitors and related antidepressants (fluoxetine, sertraline, escitalopram, venlafaxine, duloxetine, clomipramine)
  • Triptans and opioid analgesics with serotonergic activity (sumatriptan, rizatriptan, tramadol, tapentadol, fentanyl, pethidine)
  • Over-the-counter dextromethorphan (cough suppressants) and chlorpheniramine (sedating antihistamines)
  • Carbidopa (in levodopa combinations)
  • Serotonergic supplements (L-tryptophan, S-adenosylmethionine, St. John's wort, Rhodiola rosea, Syrian rue)
  • Additive sedative and sleep supplements (melatonin, valerian, magnesium glycinate, L-theanine)
  • High-dose vitamin B6 (above roughly 50 mg daily)
  • Serotonergic anaesthetic agents around surgery, and ondansetron and similar antiemetics

Risk & Side Effects

  • High: Dose-dependent gastrointestinal adverse effects
  • Medium: Serotonin syndrome with serotonergic co-medication
  • Low: Eosinophilia and eosinophilia-myalgia syndrome; psychiatric disturbance at high doses; scleroderma-like skin disease with carbidopa co-administration
  • Speculative: Neuroendocrine activation; cardiac valve fibrosis from chronic peripheral serotonin elevation; blunting of endogenous serotonin production

Monitoring

Marker Target Why
Absolute eosinophil count Under 300 cells/µL Detects the eosinophilia that precedes eosinophilia-myalgia syndrome
Serum tryptophan 45-80 µmol/L Indicates whether precursor supply is genuinely low before adding a downstream precursor
High-sensitivity C-reactive protein Under 1.0 mg/L Inflammation diverts tryptophan away from serotonin, predicting who has headroom to gain
Serum vitamin B6 (pyridoxal-5'-phosphate) 30-80 nmol/L The cofactor required to convert 5-HTP into serotonin
Alanine aminotransferase (ALT) 10-26 U/L (women), 10-33 U/L (men) Confirms intact clearance capacity before and during use
24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA) No established target under supplementation; track against the individual's own pre-supplement value Confirms systemic serotonin turnover has risen, and flags the false-positive carcinoid result
Resting heart rate and blood pressure Under 70 bpm resting; under 120/80 mmHg Rising values with tremor or agitation are the earliest bedside sign of serotonin excess

Cadence: Baseline before starting; blood count repeated at 8-12 weeks, then every 6-12 months where use continues; chosen outcome score at 4 weeks and 12 weeks

Qualitative Assessment

  • Sleep onset latency and number of night-time awakenings, tracked nightly
  • Residual morning sedation or vivid, disruptive dreaming, which usually indicate too high an evening dose
  • Mood stability across the day, and any emergence of agitation, restlessness or unusual elation
  • Early satiety at meals and the strength of evening carbohydrate cravings
  • Nausea, loose stools or abdominal cramping, and whether these settle after the first two weeks
  • Cognitive clarity, word-finding and short-term memory
  • Any new muscle pain, skin tightening or unexplained rash, which is the trigger for an immediate stop and a blood count